Advertisement
Table 1 Clinical characteristics according to treatment (N = 30)
| Characteristics | X-ray (n = 22) | Proton (n = 8) | p value |
|---|---|---|---|
| Age [years; median (range)] | 75 (55–84) | 77 (62–85) | 0.640 |
| Sex | |||
| Female | 0 (0%) | 1 (12.5%) | 0.092 |
| Male | 22 (100%) | 7 (87.5%) | |
| Smoking Status | |||
| Never smoker | 0 (0%) | 1 (12.5%) | 0.092 |
| Current or Ex-smoker | 22 (100%) | 7 (87.5%) | |
| ECOG performance | |||
| 0–1 | 13 (59.1%) | 8 (100%) | 0.031 |
| 2–3 | 9 (40.9%) | 0 (0%) | |
| Clinical Stage | |||
| IA-IB | 15 (68.2%) | 4 (50.0%) | 0.361 |
| IIA-IIB | 7 (31.8%) | 4 (50.0%) | |
| Histology | |||
| Adenocarcinoma | 5 (31.3%) | 2 (28.6%) | 0.775 |
| Squamous cell carcinoma | 10 (62.5%) | 5 (71.4%) | |
| Others | 1 (6.2%) | 0 (0%) | |
| Not proven | 6 | 1 | |
| Pulmonary function test | |||
| FEV1 | |||
| > 50% | 21 (95.5%) | 8 (100%) | 0.540 |
| ≤ 50% | 1 (4.5%) | 0 (0%) | |
| DLCO | |||
| > 60% | 9 (40.9%) | 2 (25.0%) | 0.424 |
| ≤ 60% | 13 (59.1%) | 6 (75.0%) | |
| DLCO | |||
| > 40% | 20 (90.9%) | 7 (87.5%) | 0.783 |
| ≤ 40% | 2 (9.1%) | 1 (12.5%) | |
| GAP index | |||
| 1 | 9 (40.9%) | 1 (12.5%) | 0.144 |
| 2–3 | 13 (59.1%) | 7 (87.5%) | |
